Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00232336 · ClinicalTrials.gov registry record · Phase 4
Quetiapine for Cocaine Use and Cravings
A Phase 4 study of Substance-Related Disorders and Cocaine-Related Disorders, sponsored by Seattle Institute for Biomedical and Clinical Research.
- Completed
- Registry status
- Phase 4
- Development phase
- 42
- Enrollment target
- 1
- Study location
NCT00232336 is a Phase 4 study of Substance-Related Disorders and Cocaine-Related Disorders that has completed, run by Seattle Institute for Biomedical and Clinical Research. The registered enrollment target is 42 participants, below the 1,520-participant average among 58 other Substance-Related Disorders trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00232336, a Phase 4 study of Substance-Related Disorders and Cocaine-Related Disorders, has completed, sponsored by Seattle Institute for Biomedical and Clinical Research.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 42 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study was to collect pilot data on whether quetiapine may be effective in the reduction of cocaine use and cravings in cocaine dependent individuals.
Conditions Studied
Interventions
- DRUG quetiapine
Study Locations (1)
Washington
- VA Puget Sound Health Care System, American Lake Division - Tacoma
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2003-10 |
| Est. Completion | 2006-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00232336
The ClinicalTrials.gov registry entry for NCT00232336 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,520-participant average among 58 other Substance-Related Disorders trials with a reported enrollment target (97% lower). The listed sponsor is Seattle Institute for Biomedical and Clinical Research, which has 43 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Substance-Related Disorders appearing as the primary indexed condition, and to 1 intervention - of which quetiapine is the first listed.
NCT00232336 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.
Frequently Asked Questions
What is clinical trial NCT00232336 about?
NCT00232336 is a clinical study titled "Quetiapine for Cocaine Use and Cravings". The purpose of this study was to collect pilot data on whether quetiapine may be effective in the reduction of cocaine use and cravings in cocaine dependent individuals.
What is the current status of trial NCT00232336?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 42 participants. The study started on 2003-10. Estimated completion is 2006-01.
What conditions does trial NCT00232336 study?
This clinical trial studies the following conditions: Substance-Related Disorders, Cocaine-Related Disorders.
What interventions are being tested in trial NCT00232336?
The interventions under investigation include: quetiapine (DRUG).
Who is sponsoring clinical trial NCT00232336?
This trial is sponsored by Seattle Institute for Biomedical and Clinical Research, which has 43 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00232336 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Substance-Related Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Modeling Impaired Judgement in Cocaine Abusers - 6
COMPLETED · Phase 4
-
Relapse Prevention With Varenicline
COMPLETED · Phase 4
-
Buprenorphine/Naloxone in the Treatment of Heroin Dependence - 14
COMPLETED · Phase 4
-
Methylphenidate Raclopride Positron Emission Tomography (PET) Test - 11
COMPLETED · Phase 4
-
Buprenorphine and Integrated HIV Care
COMPLETED · Phase 4
-
Integration of Buprenorphine Into HIV Clinical Settings - Primary Care Model (PCM)
COMPLETED · Phase 4
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.